Central Nervous System Stimulant Drug Class List

Drugs in Drug Class: Central Nervous System Stimulant

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Aurobindo Pharma Ltd	ACETAMINOPHEN, ASPIRIN AND CAFFEINE	acetaminophen; aspirin; caffeine	TABLET;ORAL	211695-001	Feb 2, 2022		OTC	No	No
Granules	ACETAMINOPHEN, ASPIRIN AND CAFFEINE	acetaminophen; aspirin; caffeine	TABLET;ORAL	214039-001	Feb 23, 2021		OTC	No	No
Perrigo	ACETAMINOPHEN, ASPIRIN AND CAFFEINE	acetaminophen; aspirin; caffeine	TABLET;ORAL	075794-001	Nov 26, 2001		OTC	No	No
Takeda Pharms Usa	ADDERALL XR 10	amphetamine aspartate; amphetamine sulfate; dextroamphetamine saccharate; dextroamphetamine sulfate	CAPSULE, EXTENDED RELEASE;ORAL	021303-001	Oct 11, 2001	AB1	RX	Yes	No
Takeda Pharms Usa	ADDERALL XR 15	amphetamine aspartate; amphetamine sulfate; dextroamphetamine saccharate; dextroamphetamine sulfate	CAPSULE, EXTENDED RELEASE;ORAL	021303-006	May 22, 2002	AB1	RX	Yes	No
Takeda Pharms Usa	ADDERALL XR 20	amphetamine aspartate; amphetamine sulfate; dextroamphetamine saccharate; dextroamphetamine sulfate	CAPSULE, EXTENDED RELEASE;ORAL	021303-002	Oct 11, 2001	AB1	RX	Yes	No
Takeda Pharms Usa	ADDERALL XR 25	amphetamine aspartate; amphetamine sulfate; dextroamphetamine saccharate; dextroamphetamine sulfate	CAPSULE, EXTENDED RELEASE;ORAL	021303-004	May 22, 2002	AB1	RX	Yes	No

Central Nervous System Stimulant Market Analysis and Financial Projection

The global Central Nervous System (CNS) stimulant drugs market is undergoing transformative growth, driven by rising neurological disorder rates and evolving therapeutic innovations. Below is a comprehensive analysis of market dynamics and patent trends shaping this sector.

---

Market Dynamics

Growth Drivers

1. Rising ADHD Prevalence:
   The market is primarily propelled by a surge in ADHD diagnoses, affecting an estimated 366 million adults and 6.1 million children globally[1][10]. Increased awareness and improved diagnostic tools have amplified treatment demand, with prescriptions for CNS stimulants rising by 32% among adults in 2022–2023[10].

2. Sleep Apnea and Narcolepsy Treatment:
   CNS stimulants like pitolisant (a non-controlled antihistamine) are increasingly used to manage excessive daytime sleepiness in sleep apnea and narcolepsy patients, driven by their efficacy and lower abuse potential compared to traditional stimulants[8][7].

3. Mental Health Awareness:
   Global efforts to destigmatize mental health have expanded treatment access. Over 970 million people suffered from mental disorders in 2019, with ADHD and depression being key targets for stimulant therapies[1].

4. Geriatric Population Growth:
   Aging demographics and associated cognitive decline are fostering demand for CNS stimulants. By 2050, the elderly population (≥60 years) is projected to reach 2 billion, increasing the incidence of neurodegenerative conditions[12].

Market Challenges

• Safety and Abuse Risks:
  Stimulants like methylphenidate and amphetamines face scrutiny due to dependency risks, particularly among adolescents. Side effects include cardiovascular issues and seizures, which have led to stricter prescribing guidelines[7][1].
• Generic Competition:
  Patent expirations (e.g., Copaxone) and generic entrants like Actavis’ methylphenidate patch threaten branded drug revenues, though litigation settlements (e.g., Daytrana in 2015) temporarily mitigate this[9][12].
• Regulatory Hurdles:
  Lengthy clinical trials and safety requirements delay drug approvals, escalating R&D costs[6].

Regional Insights

• North America Dominance:
  Accounting for over half of global neurological clinical trials, the U.S. and Canada lead due to high ADHD prevalence (1.8 million Canadians affected) and advanced healthcare infrastructure[10].
• Emerging Markets:
  Asia-Pacific shows growth potential with rising mental health investments and untapped patient populations[10].

Innovation Trends

• Third-Generation Drugs:
  Newer agents like lacosamide and eslicarbazepine offer fewer side effects and broader therapeutic ranges, enhancing adoption[7].
• Non-Stimulant Alternatives:
  Drugs such as Supernus’ SPN-812 (a norepinephrine reuptake inhibitor) and atomoxetine address abuse concerns while maintaining efficacy in ADHD treatment[4][5].

---

Patent Landscape

Key Patents and Innovations

Patent/Innovation	Key Contribution	Status/Impact
US2892753A (1957)	Introduced CNS stimulants without euphoric side effects	Expired, foundational for non-euphoric stimulant development[2]
SPN-812 Patents (2014)	Covers non-stimulant ADHD treatment; extends market exclusivity until 2030+	Strengthens Supernus’ position in ADHD therapeutics[4]
Pitolisant (H₃ Antagonist)	First non-controlled anti-narcoleptic with minimal abuse risk	Marketed as Wakix®, expanding narcolepsy treatment options[8]
Prolintane Synthesis	Efficient synthesis method for stimulant Prolintane (Katovit®)	Facilitates cost-effective production of niche CNS agents[13]

Legal and Competitive Developments

• Daytrana Litigation:
  Actavis secured a 2015 license to produce generic methylphenidate patches, leveraging 180-day exclusivity periods to capture market share[9].
• Screening Innovations:
  Methods like Drosophila melanogaster models (US6541193B2) streamline neuroactive drug testing, reducing R&D timelines[11].

---

Future Outlook

The CNS stimulant market is poised to exceed USD 23.9 billion by 2037, supported by ADHD and sleep disorder trends[1]. Innovations in drug delivery (e.g., transdermal patches) and non-stimulant therapies will drive growth, while AI-driven diagnostics and personalized medicine could revolutionize treatment paradigms[6][7]. However, regulatory pressures and generic competition will necessitate continuous innovation to sustain profitability.

"The integration of non-stimulant alternatives and advanced drug-delivery systems is redefining ADHD and narcolepsy care, balancing efficacy with safety."
— Research and Markets Analysis, 2024[6]

References

1. https://www.researchnester.com/reports/central-nervous-system-stimulant-drugs-market/5524
2. https://patents.google.com/patent/US2892753A/en
3. https://www.expertmarketresearch.com/reports/central-nervous-system-stimulant-drugs-market
4. https://ir.supernus.com/news-releases/news-release-details/supernus-announces-issuance-first-use-patents-protecting-spn-812
5. https://openstax.org/books/pharmacology/pages/13-5-cns-stimulants-and-nonstimulants
6. https://www.researchandmarkets.com/reports/6010786/central-nervous-system-drugs-market-drug
7. https://healthcareasiamagazine.com/healthcare/news/what-lies-ahead-central-nervous-system-stimulant-drugs-market
8. https://en.wikipedia.org/wiki/Stimulant
9. https://www.drugdiscoverytrends.com/actavis-settles-daytrana-patent-challenge/
10. https://www.mordorintelligence.com/industry-reports/central-nervous-system-stimulant-drugs-market
11. https://patents.google.com/patent/US6541193B2/en
12. https://www.databridgemarketresearch.com/reports/global-cns-stimulants-market
13. https://pdfs.semanticscholar.org/d56a/322e8e8a6fd2bd929d1464df24e5a73b4582.pdf
14. https://opentextbc.ca/nursingpharmacology/chapter/8-6-cns-stimulants/